I-O Optimise is a novel observational research initiative that is providing insights into the real-world management of thoracic malignancies*. By bringing together teams of clinicians who each hold part of the data puzzle under one umbrella, I-O Optimise provides responses to some of the challenges facing modern cancer care. The deeper understanding of disease characteristics, treatment patterns and cancer outcomes that I-O Optimise aims to provide is important for oncologists and other healthcare professionals, as well as for academic researchers, payers and regulators. Ultimately, these new insights could help to transform future patient care.

I-O Optimise is a multinational collaborative initiative established by Bristol Myers Squibb. The External Scientific Committee, a multidisciplinary team of healthcare professionals and scientists, plays a key role in I-O Optimise by guiding research prioritisation and publication focus. Patient advocates and data source experts provide added value to the programme through their support at ongoing engagements and events.

High standards of privacy and data protection, information governance and security are ensured in the handling of all patient data in I-O Optimise.

*I-O Optimise is generating data for non-small cell lung cancer, small cell lung cancer and malignant pleural mesothelioma.